US Stock MarketDetailed Quotes

Atrium Therapeutics (RNA)

Watchlist
  • 13.230
  • -0.040-0.30%
Close May 15 16:00 ET
  • 13.230
  • 0.0000.00%
Post 20:01 ET
226.31MMarket Cap-3.86P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Atrium Therapeutics (RNA) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2026
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(FY)Dec 31, 2023
Total revenue
1,148.25%19.64M
70.85%18.62M
-71.11%859K
1.57M
11.60%10.9M
2.97M
9.76M
Operating revenue
1,148.25%19.64M
70.85%18.62M
-71.11%859K
--1.57M
11.60%10.9M
--2.97M
--9.76M
Cost of revenue
Gross profit
Operating expense
309.03%36.92M
295.74%95.43M
430.07%48.89M
9.03M
49.32%24.12M
9.22M
16.15M
Selling and administrative expenses
870.21%20.26M
747.76%41.68M
1,682.82%30.4M
--2.09M
40.58%4.92M
--1.71M
--3.5M
-General and administrative expense
870.21%20.26M
747.76%41.68M
1,682.82%30.4M
--2.09M
40.58%4.92M
--1.71M
--3.5M
Research and development costs
140.12%16.66M
179.99%53.76M
146.00%18.5M
--6.94M
51.73%19.2M
--7.52M
--12.65M
Operating profit
-131.88%-17.28M
-481.13%-76.81M
-668.44%-48.04M
-7.45M
-106.98%-13.22M
-6.25M
-6.39M
Net non-operating interest income expense
Other net income (expense)
21,466.67%647K
-700.00%-12K
0
3K
100.00%2K
4K
1K
Other non- operating income (expenses)
21,466.67%647K
-700.00%-12K
--0
--3K
100.00%2K
--4K
--1K
Income before tax
-123.29%-16.63M
-481.31%-76.83M
-668.93%-48.04M
-7.45M
-106.99%-13.22M
-6.25M
-6.39M
Income tax
-101.19%-142K
-99.35%34K
11.91M
5.27M
0
Net income
-123.29%-16.63M
-205.25%-76.68M
-317.56%-48.07M
-7.45M
-293.45%-25.12M
-11.51M
-6.39M
Net income continuous Operations
-123.29%-16.63M
-205.25%-76.68M
-317.56%-48.07M
---7.45M
-293.45%-25.12M
---11.51M
---6.39M
Minority interest income
Net income attributable to the parent company
-123.29%-16.63M
-205.25%-76.68M
-317.56%-48.07M
-7.45M
-293.45%-25.12M
-11.51M
-6.39M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-123.29%-16.63M
-205.25%-76.68M
-317.56%-48.07M
-7.45M
-293.45%-25.12M
-11.51M
-6.39M
Basic earnings per share
-122.47%-0.97
-205.19%-4.48
-317.01%-2.81
-0.436
-293.45%-1.4679
-0.6738
-0.3731
Diluted earnings per share
-122.47%-0.97
-205.19%-4.48
-317.03%-2.8101
-0.436
-293.45%-1.4679
-0.6738
-0.3731
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
(Q1)Mar 31, 2026(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(FY)Dec 31, 2023
Total revenue 1,148.25%19.64M70.85%18.62M-71.11%859K1.57M11.60%10.9M2.97M9.76M
Operating revenue 1,148.25%19.64M70.85%18.62M-71.11%859K--1.57M11.60%10.9M--2.97M--9.76M
Cost of revenue
Gross profit
Operating expense 309.03%36.92M295.74%95.43M430.07%48.89M9.03M49.32%24.12M9.22M16.15M
Selling and administrative expenses 870.21%20.26M747.76%41.68M1,682.82%30.4M--2.09M40.58%4.92M--1.71M--3.5M
-General and administrative expense 870.21%20.26M747.76%41.68M1,682.82%30.4M--2.09M40.58%4.92M--1.71M--3.5M
Research and development costs 140.12%16.66M179.99%53.76M146.00%18.5M--6.94M51.73%19.2M--7.52M--12.65M
Operating profit -131.88%-17.28M-481.13%-76.81M-668.44%-48.04M-7.45M-106.98%-13.22M-6.25M-6.39M
Net non-operating interest income expense
Other net income (expense) 21,466.67%647K-700.00%-12K03K100.00%2K4K1K
Other non- operating income (expenses) 21,466.67%647K-700.00%-12K--0--3K100.00%2K--4K--1K
Income before tax -123.29%-16.63M-481.31%-76.83M-668.93%-48.04M-7.45M-106.99%-13.22M-6.25M-6.39M
Income tax -101.19%-142K-99.35%34K11.91M5.27M0
Net income -123.29%-16.63M-205.25%-76.68M-317.56%-48.07M-7.45M-293.45%-25.12M-11.51M-6.39M
Net income continuous Operations -123.29%-16.63M-205.25%-76.68M-317.56%-48.07M---7.45M-293.45%-25.12M---11.51M---6.39M
Minority interest income
Net income attributable to the parent company -123.29%-16.63M-205.25%-76.68M-317.56%-48.07M-7.45M-293.45%-25.12M-11.51M-6.39M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -123.29%-16.63M-205.25%-76.68M-317.56%-48.07M-7.45M-293.45%-25.12M-11.51M-6.39M
Basic earnings per share -122.47%-0.97-205.19%-4.48-317.01%-2.81-0.436-293.45%-1.4679-0.6738-0.3731
Diluted earnings per share -122.47%-0.97-205.19%-4.48-317.03%-2.8101-0.436-293.45%-1.4679-0.6738-0.3731
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +34.01%
Sample Name
Sample Code
 +27.74%
Sample Name
Sample Code
 +26.87%
4
United States Gasoline Fund Lp
UGA
+26.33%
5
Powershares Db Multi-Sector Commodi Powershares Db Oil Fund
DBO
+20.91%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +11.54%
Sample Name
Sample Code
 +10.70%
Sample Name
Sample Code
 +6.24%
4
NIO Inc
NIO
+4.27%
5
Hesai
HSAI
+3.89%
View More
Middle East conflict spreads to the stock market! How should investors respond?
According to Axios, on Sunday local time, Trump rejected Iran's latest ceasefire proposal, prompting a sharp response from Iran: no one woul Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -